20248-64-0

Basic information

• Product Name: 4,6-Dichloro-1,3-phenylenediamine
• Synonyms: 1,5-Diamino-2,4-dichlorobenzene;4,6-Dichloro-1,3-phenylenediamine;(5-amino-2,4-dichloro-phenyl)amine;4,6-dichlorobenzene-1,3-diamine;1,3-Benzenediamine,4,6-dichloro-
• CAS NO: 20248-64-0
• Molecular Formula: C₆H₆Cl₂N₂
• Molecular Weight: 177.03
• Mol File: 20248-64-0.mol
• Article Data: 8

Chemical Properties

• Melting Point: 138-139 °C
• Boiling Point: 313.2 °C at 760 mmHg
• Flash Point: 143.2 °C
• Appearance: /
• Density: 1.501 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2.30±0.10(Predicted)
• CAS DataBase Reference: 4,6-Dichloro-1,3-phenylenediamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-Dichloro-1,3-phenylenediamine(20248-64-0)
• EPA Substance Registry System: 4,6-Dichloro-1,3-phenylenediamine(20248-64-0)

Safety Data

• Hazardous Substances Data: 20248-64-0(Hazardous Substances Data)

Usage

General Description

4,6-Dichloro-1,3-phenylenediamine, also known as p-Phenylenediamine, is an organic compound with the chemical formula C6H6Cl2N2. It is a colorless solid that is soluble in water and commonly used as a component in hair dyes and black rubber. This chemical is known to cause allergic reactions in some individuals and has been classified as a skin and respiratory irritant. It is important to handle this chemical with caution and to follow safety guidelines when working with it.

Upstream product

• 3698-83-7 2,4-dichloro-1,5-dinitrobenzene 
• 10268-78-7 1,3-diacetylaminobenzene 
• 1061716-31-1 N,N'-(4,6-dichloro-m-phenylene)-bis-acetamide 

Downstream Products

• 916052-26-1 N-(2,4-dichloro-5-{[(5Z)-4-oxo-5-(6-quinolinylmethylidene)-4,5-dihydro-1,3-thiazol-2-yl]amino}phenyl)cyclobutanecarboxamide 
• 916052-28-3 N-{2,4-dichloro-5-[(4-oxo-4,5-dihydro-1,3-thiazol-2-yl)amino]phenyl}cyclobutanecarboxamide 
• 1353989-21-5 N-benzyl-6,8-dichloro-1-methyl-2-oxo-1,2-dihydropyrrolo[4,3,2-d,e]quinoline-4-carboxamide 
• 1353989-08-8 dimethyl 5-amino-6,8-dichloro-4-hydroxy-1,2,3,4-tetrahydroquinoline-2,4-dicarboxylate 
• 69132-90-7 N-(3-amino-4,6-dichlorophenyl)-γ-chlorobutyramide 
• 53882-22-7 N,N'-(4,6-Dichloro-m-phenylene)dioxamic acid 
• 259092-66-5 2-bromo-4,6-dichloro-1,3-phenylenediamine 
• 3698-83-7 2,4-dichloro-1,5-dinitrobenzene 
• 252265-68-2 1,5-dichloro-2,4-dinitrosobenzene 
• 53882-23-8 Diethyl (4,6-dichloro-m-phenylene)dioxamate 
• 95-94-3 1,2,4,5-tetrachlorobenzene 
• 5926-53-4 4,6-dichloro-m-phenylene diisocyanate 
• 259092-71-2 4-bromo-2,6-bis(tert-butyl-NNO-azoxy)-5-chloro-1,3-phenylenediamine 
• 252265-74-0 2-bromo-4,6-bis(tert-butyl-NNO-azoxy)-1,3-phenylenediamine 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Design, synthesis, and biological evaluation of potent quinoline and pyrroloquinoline ammosamide analogues as inhibitors of quinone reductase 2

A variety of ammosamide B analogues have been synthesized and evaluated as inhibitors of quinone reductase 2 (QR2). The potencies of the resulting series of QR2 inhibitors range from 4.1 to 25,200 nM. The data provide insight into the structural parameters necessary for QR2 inhibitory activity. The natural product ammosamide B proved to be a potent QR2 inhibitor, and the potencies of the analogues generally decreased as their structures became more distinct from that of ammosamide B. Methylation of the 8-amino group of ammosamide B was an exception, resulting in an increase in quinone reductase 2 inhibitory activity from an IC50 of 61 nM to IC50 4.1 nM.

NOVEL CHEMICAL COMPOUNDS

This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with hYAK3 activity.